Research and Technology Development

Misvik´s Cell Panel screening service provides you a cost-effective approach to test your drugs and molecules as single agents or as combinations across hundreds of cancer cell lines to rapidly assess therapy efficacy and drug responses across a broad spectrum of solid human cancer lineages. Our routine HTS services include:

• Screening across the 150-cell line MISB Cancer Cell Line Panel or your selection of models of interest.
• 384-well format screening with customer defined dosing, schedule and readouts.
• 12-/24-well format colony efficiency assays from long term readouts.
• Tumor-immune cell co-culture assays.
• Bliss matrix combination screening for drug synergy and scheduling

Misvik´s team has 20+ years experience on phenotypic cell-based drug and fuctional genetic screening. Our scientist have published and co-authored 100+ high-throughput screening papers across all the four star journals including Science, Nature and Cell. Using our expertise, we can convert your marker of interest into an ultra-high content and throughput screen readout or offer our suite of readily established assays for the study of e.g.,:

• Therapeutic efficacy; profiferation, cell cycle and apoptosis
• DNA damage responses and senescence
• Lineage heterogeneity and transitioning
• Tumor-immune cell interactions

Misvik has one of the largest active RPPA (reverse-phase-protein-array) manufacturing facilities in the Northern Europe. Consisting of two pilot scale contact microarray printers and two industrial scale printers for scale-up and massively parallel array manufacturing, we are your one-stop-shop for any protein microarray manufacturing needs. With 15+ years´ experience on RPPA and other miniaturized microarray methods, we can support both cell-based functional screening using RPPA readouts as well as ultra-high-throughput multiplexed analyses of our in-house collected patient samples of 700+ patient derived tissue and cell line samples from 65+ different human cancer types or your proprietary tissue collections.

• Cell-based functional screening using RPPA readouts
• Functional immunophenotypic drug screening of immuno-oncology
• Target discovery and validation across Misvik´s ex vivo tumor models, 700+ patients samples, 90+ cancer types
• RPPA expression analysis from Client´s cell or tissue samples

Misvik´s Toxicology research provides fast, cost-effective safety evaluations with a prime focus on the predictive toxicology and DILI assessment using animal free toxicogenomics and high-throughput screening solutions. Our toxicology team is actively involved in EU-funded projects that drive the development of coming animal free test strategies and safety governance standards

• In house panel of 300 immortalized LCL cell lines for immunotoxicology modelling
• Standard cell line panels for kidney, liver and lung toxicology 
• Chemical read-across assessment and toxicity MoA grouping
• Predictive Toxicogenomic Space (PTGS) for modelling Key Events, Adverse Outcome Pathway (AOP) and DILI modelling
• Tox5-score for in vitro toxicity scoring and ranking
  
  
  

MISB Cancer Cell Line Panel – The largest private collection of solid cancer cell lines in the world. No third-party license costs for contract research

3D Organoid Microarrays – A technology for spatially controlled propagation of organoids from tumor biopsies

ARRAYIO – A proteomic based immunophetopyting technology for massively parallel functional immuno-oncology drug discovery 

RPPA tumor sample collection consisting of 700+ tumor tissue samples from 90+ different cancer types for rapid target discovery and validation, e.g., ADC target & biomarker development

MBEM – A proprietary tissue culture medium developed for pan-cancer ex vivo tissue culture applications